WEBVTT
Kind: captions
Language: en

00:00:04.529 --> 00:00:07.410 

my<00:00:05.529> name<00:00:05.740> is<00:00:05.890> Scott<00:00:06.100> Woodman<00:00:06.490> I<00:00:06.670> am<00:00:07.390> a

00:00:07.410 --> 00:00:07.420 
my name is Scott Woodman I am a

00:00:07.420 --> 00:00:09.270 
my name is Scott Woodman I am a
physician<00:00:07.960> and<00:00:08.200> researcher<00:00:08.469> at<00:00:09.100> the

00:00:09.270 --> 00:00:09.280 
physician and researcher at the

00:00:09.280 --> 00:00:11.400 
physician and researcher at the
University<00:00:09.790> of<00:00:09.820> Texas<00:00:10.059> MD<00:00:10.510> Anderson<00:00:10.660> Cancer

00:00:11.400 --> 00:00:11.410 
University of Texas MD Anderson Cancer

00:00:11.410 --> 00:00:13.560 
University of Texas MD Anderson Cancer
Center<00:00:11.820> today<00:00:12.820> I'd<00:00:12.940> like<00:00:13.059> to<00:00:13.179> talk<00:00:13.330> to<00:00:13.480> you

00:00:13.560 --> 00:00:13.570 
Center today I'd like to talk to you

00:00:13.570 --> 00:00:16.620 
Center today I'd like to talk to you
about<00:00:13.630> metastatic<00:00:14.259> uveal<00:00:15.009> melanoma<00:00:15.630> uveal

00:00:16.620 --> 00:00:16.630 
about metastatic uveal melanoma uveal

00:00:16.630 --> 00:00:18.420 
about metastatic uveal melanoma uveal
melanoma<00:00:17.020> is<00:00:17.140> a<00:00:17.169> form<00:00:17.560> of<00:00:17.680> melanoma<00:00:18.220> that

00:00:18.420 --> 00:00:18.430 
melanoma is a form of melanoma that

00:00:18.430 --> 00:00:20.670 
melanoma is a form of melanoma that
begins<00:00:18.849> in<00:00:19.029> the<00:00:19.119> eye<00:00:19.150> and<00:00:20.110> although<00:00:20.410> if<00:00:20.470> it<00:00:20.529> can

00:00:20.670 --> 00:00:20.680 
begins in the eye and although if it can

00:00:20.680 --> 00:00:23.010 
begins in the eye and although if it can
be<00:00:20.770> adequately<00:00:21.189> treated<00:00:21.610> in<00:00:21.849> most<00:00:22.060> cases<00:00:22.329> in

00:00:23.010 --> 00:00:23.020 
be adequately treated in most cases in

00:00:23.020 --> 00:00:25.769 
be adequately treated in most cases in
the<00:00:23.410> eye<00:00:23.970> unfortunately<00:00:24.970> in<00:00:25.210> a<00:00:25.390> little<00:00:25.630> less

00:00:25.769 --> 00:00:25.779 
the eye unfortunately in a little less

00:00:25.779 --> 00:00:28.290 
the eye unfortunately in a little less
than<00:00:25.960> half<00:00:26.020> of<00:00:26.410> cases<00:00:26.619> it<00:00:27.279> can<00:00:27.550> go<00:00:27.669> beyond<00:00:28.090> the

00:00:28.290 --> 00:00:28.300 
than half of cases it can go beyond the

00:00:28.300 --> 00:00:32.240 
than half of cases it can go beyond the
eye<00:00:28.329> to<00:00:29.050> other<00:00:29.200> parts<00:00:29.590> of<00:00:29.800> the<00:00:30.040> body

00:00:32.240 --> 00:00:32.250 

00:00:32.250 --> 00:00:34.200 

significant<00:00:33.250> advances<00:00:33.700> have<00:00:33.850> been<00:00:33.880> made<00:00:34.000> in

00:00:34.200 --> 00:00:34.210 
significant advances have been made in

00:00:34.210 --> 00:00:38.610 
significant advances have been made in
our<00:00:34.870> understanding<00:00:35.170> of<00:00:35.680> uveal<00:00:36.040> melanoma<00:00:37.620> gene

00:00:38.610 --> 00:00:38.620 
our understanding of uveal melanoma gene

00:00:38.620 --> 00:00:40.829 
our understanding of uveal melanoma gene
mutations<00:00:39.160> have<00:00:39.339> been<00:00:39.370> found<00:00:39.730> in<00:00:40.269> two<00:00:40.600> genes

00:00:40.829 --> 00:00:40.839 
mutations have been found in two genes

00:00:40.839 --> 00:00:44.759 
mutations have been found in two genes
gene<00:00:41.260> AQ<00:00:41.649> and<00:00:41.890> gene<00:00:42.249> a<00:00:42.399> 11<00:00:42.820> in<00:00:43.179> about<00:00:43.510> 85%<00:00:44.140> of

00:00:44.759 --> 00:00:44.769 
gene AQ and gene a 11 in about 85% of

00:00:44.769 --> 00:00:48.509 
gene AQ and gene a 11 in about 85% of
cases<00:00:45.719> also<00:00:46.890> gene<00:00:47.890> mutations<00:00:48.370> have<00:00:48.489> been

00:00:48.509 --> 00:00:48.519 
cases also gene mutations have been

00:00:48.519 --> 00:00:51.509 
cases also gene mutations have been
found<00:00:48.909> in<00:00:49.089> another<00:00:49.359> gene<00:00:49.629> called<00:00:49.659> bap1<00:00:50.519> bap1

00:00:51.509 --> 00:00:51.519 
found in another gene called bap1 bap1

00:00:51.519 --> 00:00:54.029 
found in another gene called bap1 bap1
in<00:00:52.510> about<00:00:52.809> eighty-five<00:00:53.320> percent<00:00:53.469> of<00:00:53.829> tumors

00:00:54.029 --> 00:00:54.039 
in about eighty-five percent of tumors

00:00:54.039 --> 00:00:57.270 
in about eighty-five percent of tumors
that<00:00:54.219> ultimately<00:00:54.940> metastasize<00:00:56.280> knowing

00:00:57.270 --> 00:00:57.280 
that ultimately metastasize knowing

00:00:57.280 --> 00:00:59.489 
that ultimately metastasize knowing
these<00:00:57.460> gene<00:00:57.760> mutations<00:00:58.329> and<00:00:58.659> the<00:00:59.170> effects

00:00:59.489 --> 00:00:59.499 
these gene mutations and the effects

00:00:59.499 --> 00:01:01.739 
these gene mutations and the effects
they<00:00:59.589> can<00:00:59.800> have<00:01:00.010> on<00:01:00.039> cells<00:01:00.460> allows<00:01:01.390> us<00:01:01.629> the

00:01:01.739 --> 00:01:01.749 
they can have on cells allows us the

00:01:01.749 --> 00:01:03.959 
they can have on cells allows us the
opportunity<00:01:01.780> to<00:01:02.589> potentially<00:01:02.979> block<00:01:03.609> those

00:01:03.959 --> 00:01:03.969 
opportunity to potentially block those

00:01:03.969 --> 00:01:07.950 
opportunity to potentially block those
effects<00:01:04.510> with<00:01:05.050> particular<00:01:05.440> therapeutics<00:01:06.960> in

00:01:07.950 --> 00:01:07.960 
effects with particular therapeutics in

00:01:07.960 --> 00:01:09.720 
effects with particular therapeutics in
addition<00:01:08.320> to<00:01:08.440> the<00:01:08.560> genetic<00:01:08.730> understanding

00:01:09.720 --> 00:01:09.730 
addition to the genetic understanding

00:01:09.730 --> 00:01:11.940 
addition to the genetic understanding
that<00:01:09.880> we<00:01:10.000> have<00:01:10.210> of<00:01:10.390> uveal<00:01:10.810> melanoma<00:01:11.380> there

00:01:11.940 --> 00:01:11.950 
that we have of uveal melanoma there

00:01:11.950 --> 00:01:13.920 
that we have of uveal melanoma there
have<00:01:12.040> been<00:01:12.130> significant<00:01:12.880> advances<00:01:13.450> made<00:01:13.660> in

00:01:13.920 --> 00:01:13.930 
have been significant advances made in

00:01:13.930 --> 00:01:17.490 
have been significant advances made in
skin<00:01:14.590> melanoma<00:01:15.340> in<00:01:15.790> with<00:01:16.720> therapies<00:01:17.200> that

00:01:17.490 --> 00:01:17.500 
skin melanoma in with therapies that

00:01:17.500 --> 00:01:20.490 
skin melanoma in with therapies that
unleash<00:01:18.340> the<00:01:18.640> immune<00:01:19.060> system<00:01:19.570> to<00:01:19.600> fight<00:01:19.840> the

00:01:20.490 --> 00:01:20.500 
unleash the immune system to fight the

00:01:20.500 --> 00:01:22.530 
unleash the immune system to fight the
melanoma<00:01:21.130> and<00:01:21.730> we<00:01:21.940> think<00:01:22.270> there's<00:01:22.450> an

00:01:22.530 --> 00:01:22.540 
melanoma and we think there's an

00:01:22.540 --> 00:01:24.510 
melanoma and we think there's an
opportunity<00:01:22.630> to<00:01:23.410> use<00:01:23.680> those<00:01:24.010> same

00:01:24.510 --> 00:01:24.520 
opportunity to use those same

00:01:24.520 --> 00:01:26.930 
opportunity to use those same
therapeutics<00:01:25.210> in<00:01:25.420> uveal<00:01:25.930> melanoma

00:01:26.930 --> 00:01:26.940 
therapeutics in uveal melanoma

00:01:26.940 --> 00:01:29.880 
therapeutics in uveal melanoma
ultimately<00:01:27.960> there<00:01:28.960> may<00:01:29.110> be<00:01:29.140> a<00:01:29.320> wonderful

00:01:29.880 --> 00:01:29.890 
ultimately there may be a wonderful

00:01:29.890 --> 00:01:31.950 
ultimately there may be a wonderful
opportunity<00:01:30.130> to<00:01:30.520> take<00:01:30.910> the<00:01:31.300> therapies<00:01:31.720> that

00:01:31.950 --> 00:01:31.960 
opportunity to take the therapies that

00:01:31.960 --> 00:01:35.490 
opportunity to take the therapies that
can<00:01:32.940> block<00:01:33.940> the<00:01:34.330> genetic<00:01:34.750> aberrations

00:01:35.490 --> 00:01:35.500 
can block the genetic aberrations

00:01:35.500 --> 00:01:37.670 
can block the genetic aberrations
effects<00:01:36.430> that<00:01:36.670> are<00:01:36.820> occurring<00:01:37.120> in<00:01:37.210> the<00:01:37.300> cells

00:01:37.670 --> 00:01:37.680 
effects that are occurring in the cells

00:01:37.680 --> 00:01:40.110 
effects that are occurring in the cells
unleash<00:01:38.680> the<00:01:38.920> immune<00:01:39.160> system<00:01:39.580> to<00:01:39.760> fight<00:01:39.790> the

00:01:40.110 --> 00:01:40.120 
unleash the immune system to fight the

00:01:40.120 --> 00:01:43.430 
unleash the immune system to fight the
tumor<00:01:40.330> and<00:01:40.720> combine<00:01:41.470> those<00:01:41.860> two<00:01:42.160> therapies

00:01:43.430 --> 00:01:43.440 
tumor and combine those two therapies

00:01:43.440 --> 00:01:47.340 
tumor and combine those two therapies
I'm<00:01:44.440> very<00:01:44.740> fortunate<00:01:45.040> to<00:01:45.640> work<00:01:45.790> at<00:01:46.350> MD

00:01:47.340 --> 00:01:47.350 
I'm very fortunate to work at MD

00:01:47.350 --> 00:01:49.020 
I'm very fortunate to work at MD
Anderson<00:01:47.680> Cancer<00:01:47.710> Center<00:01:48.310> where<00:01:48.670> we<00:01:48.820> have<00:01:49.000> a

00:01:49.020 --> 00:01:49.030 
Anderson Cancer Center where we have a

00:01:49.030 --> 00:01:51.180 
Anderson Cancer Center where we have a
uveal<00:01:49.450> melanoma<00:01:49.930> program<00:01:50.350> that<00:01:51.040> has

00:01:51.180 --> 00:01:51.190 
uveal melanoma program that has

00:01:51.190 --> 00:01:53.400 
uveal melanoma program that has
ophthalmologists<00:01:52.180> medical<00:01:52.630> oncologists

00:01:53.400 --> 00:01:53.410 
ophthalmologists medical oncologists

00:01:53.410 --> 00:01:55.320 
ophthalmologists medical oncologists
radiation<00:01:53.800> oncologist<00:01:54.580> surgeons<00:01:55.060> and

00:01:55.320 --> 00:01:55.330 
radiation oncologist surgeons and

00:01:55.330 --> 00:01:58.140 
radiation oncologist surgeons and
pathologists<00:01:55.990> were<00:01:56.260> all<00:01:56.560> focused<00:01:57.130> on<00:01:57.370> this

00:01:58.140 --> 00:01:58.150 
pathologists were all focused on this

00:01:58.150 --> 00:02:01.590 
pathologists were all focused on this
disease<00:01:58.540> and<00:01:59.310> ultimately<00:02:00.310> hopefully<00:02:01.090> we<00:02:01.420> will

00:02:01.590 --> 00:02:01.600 
disease and ultimately hopefully we will

00:02:01.600 --> 00:02:03.930 
disease and ultimately hopefully we will
be<00:02:01.780> able<00:02:01.900> to<00:02:02.170> change<00:02:02.890> the<00:02:03.100> trajectory<00:02:03.280> of<00:02:03.760> this

00:02:03.930 --> 00:02:03.940 
be able to change the trajectory of this

00:02:03.940 --> 00:02:08.100 
be able to change the trajectory of this
disease<00:02:04.270> with<00:02:04.930> our<00:02:05.080> research<00:02:05.470> and<00:02:05.800> clinical

